Selective JAK1 Inhibitor Compounds to Minimize JAK2/JAK3 Off-Target Effects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for JAK1 inhibitors that selectively inhibit JAK1 while minimizing or avoiding inhibition of JAK2 and JAK3, as existing compounds may cause hepatotoxicity and immunogenicity, and current therapies fail to effectively target JAK1 for treating inflammatory disorders, autoimmune diseases, and cancer.
Innovation Solution
Development of specific compounds, including those of general formula (I), which selectively inhibit JAK1 by incorporating various substituents that enhance selectivity and reduce off-target effects on JAK2 and JAK3, thereby providing therapeutic benefits for inflammatory and autoimmune disorders, as well as cancer treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing JAK inhibitors are used to treat inflammatory and autoimmune disorders, then JAK1 inhibition activity is achieved, but hepatotoxicity and immunogenicity occur due to lack of selectivity
Solution Approach 1:
The patent applies local quality by designing compounds with specific substituent patterns at defined positions (R1, R2, R3, R4, R5, R6, R7, R8) to achieve selective interaction with JAK1's unique binding pocket. The general formula (I) incorporates various substituent options including halogen, cyano, hydroxy, oxo, amino, and carbonyl groups at specific positions to optimize selectivity for JAK1 over JAK2 and JAK3, thereby maintaining therapeutic efficacy while reducing hepatotoxicity and immunogenicity associated with non-selective inhibition
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular parameters such as substituent types, positions, and configurations in the general formula (I) to modulate selectivity. By changing parameters like the nature of R groups (alkyl, aryl, heteroaryl, halogen, etc.), their positions on the core structure, and their stereochemical configurations, the invention optimizes the compound's affinity for JAK1 while reducing off-target effects on JAK2 and JAK3, thus improving the safety profile
2Reliability
If JAK2 is inhibited to treat inflammatory disorders, then anti-inflammatory effects are achieved, but anemia and thrombocytopenia occur as side effects
Solution Approach 1:
The patent applies local quality by designing compounds with specific substituent patterns that exploit local structural differences in the JAK1 binding pocket compared to JAK2. The general formula (I) incorporates substituents at positions R1-R8 that are specifically configured to interact with JAK1's unique amino acid residues while avoiding critical interactions with JAK2's active site, thereby achieving selective JAK1 inhibition that maintains anti-inflammatory efficacy without causing anemia and thrombocytopenia associated with JAK2 inhibition
3Adaptability or versatility
If JAK1/2 dual inhibitors are used to treat inflammatory disorders, then broad cytokine pathway coverage is achieved, but hepatotoxicity and immunogenicity increase
Solution Approach 1:
The patent applies local quality by designing compounds with specific substituent patterns that exploit local structural differences in the JAK1 binding pocket compared to JAK2. The general formula (I) incorporates substituents at positions R1-R8 that are specifically configured to interact with JAK1's unique amino acid residues while avoiding critical interactions with JAK2's active site, thereby achieving selective JAK1 inhibition that maintains anti-inflammatory efficacy without causing anemia and thrombocytopenia associated with JAK2 inhibition
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular parameters such as substituent types, positions, and configurations in the general formula (I) to modulate selectivity. By changing parameters like the nature of R groups (alkyl, aryl, heteroaryl, halogen, etc.), their positions on the core structure, and their stereochemical configurations, the invention optimizes the compound's affinity for JAK1 while reducing off-target effects on JAK2 and JAK3, thus improving the safety profile
Data Source
AI summary
Janus kinases (JAKs) inhibitors have Formula (I).